HER2 Biomarkers
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
Reveal Genomics' HER2DX Clinical Validation Trial Underway in Europe
The trial will randomize 300 patients with newly diagnosed early-stage HER2-positive breast cancer to treatment based on Reveal's test or standard therapy.
Guardant Health Receives Guardant360 CDx Regulatory Approval in Japan for HER2 Lung Cancer Treatment
Patients who test positive for a HER2 mutation and have seen their disease progress after chemotherapy can now be treated with Daiichi Sankyo's Enhertu.
AmoyDx, AstraZeneca Partner on HER2 Lung Cancer CDx Development in China
Amoy will develop a companion diagnostic for Enhertu (trastuzumab deruxtecan) under its latest agreement to develop companion diagnostics for AstraZeneca's therapies.
Consortium Aims to Standardize IHC Biomarker Tests for Precision Medicine, Starting With HER2
Premium
The Consortium for Analytic Standardization hopes to bring an archaic technology into the 21st century by producing calibrated standards for the most utilized IHC-based biomarker tests.